Private Capital Group’s Travere Therapeutics TVTX Stock Holding History

Private Capital Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$12K	Hold	475	–	–	0.01%	999
2022 Q1	$12K	Buy	475 +227	+92%	+$6.03K	﹤0.01%	1221
2021 Q4	$8K	Hold	248	–	–	﹤0.01%	1404
2021 Q3	$6K	Buy	+248	New	+$4.56K	﹤0.01%	1533
2020 Q1	–	Sell	-26	Closed	–	–	2137
2019 Q4	$0	Hold	26	–	–	﹤0.01%	2188
2019 Q3	$0	Buy	+26	New	+$430	﹤0.01%	2448
2019 Q2	–	Sell	-26	Closed	-$1K	–	2421
2019 Q1	$1K	Hold	26	–	–	﹤0.01%	2094
2018 Q4	$1K	Buy	+26	New	+$647	﹤0.01%	2106

Other funds holding TVTX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Private Capital Group's TVTX Position: Q2 2022 in Review

Private Capital Group held its Travere Therapeutics (TVTX) position steady in Q2 2022 at 475 shares worth $12K. The position accounts for 0.01% of the portfolio, ranked #999.

Private Capital Group first reported a position in TVTX in Q4 2018 and has held it in 8 quarters since. 171 funds tracked by Wall St. Rank hold TVTX as of Q2 2022.

Private Capital Group held 475 shares of Travere Therapeutics worth $12K as of Q2 2022.
Private Capital Group left its Travere Therapeutics share count unchanged in Q2 2022.
Travere Therapeutics made up 0.01% of Private Capital Group's portfolio in Q2 2022, its #999 holding.
Private Capital Group first reported a position in Travere Therapeutics in Q4 2018 and has held it in 8 quarters since.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.